上海睿昂基因科技股份有限公司 2025年年度业绩预告

Core Viewpoint - The company, Shanghai Ruian Gene Technology Co., Ltd., anticipates a significant decline in its financial performance for the year 2025, projecting a revenue drop and net losses compared to the previous year [3][5]. Financial Performance Forecast - The company expects to achieve an operating revenue between 170 million to 176 million yuan for the year 2025 [3]. - The projected net loss attributable to the parent company is estimated to be between -39.91 million to -59.86 million yuan [3]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -49.91 million to -69.86 million yuan [3]. Previous Year Performance - In 2024, the company reported an operating revenue of 242.31 million yuan and a net loss of -15.76 million yuan [5]. - The earnings per share for 2024 were -0.28 yuan per share [6]. Reasons for Performance Changes - The decline in revenue is attributed to intensified competition in the in vitro diagnostics industry and specific adverse events affecting the company, leading to a revenue decrease of approximately 66.31 million to 72.31 million yuan, representing a year-on-year decline of 27.36% to 29.84% [7]. - Slower payment collection from downstream clients due to the medical industry environment has resulted in increased provisions for bad debts [7]. - The company has halted its molecular diagnostic reagent R&D center and industrialization project, recognizing impairment losses due to the lack of a continuation plan [7]. - Impairment losses have also been recognized for subsidiaries due to deteriorating market conditions, affecting their goodwill and major assets [7]. - The overall performance decline of both the parent and subsidiary companies has led to a reassessment of deferred tax assets due to limited future taxable income [7]. Other Information - The financial data provided is preliminary and has not been audited by registered accountants [4][8]. - The company has not identified any significant uncertainties that would affect the accuracy of the performance forecast as of the announcement date [8].